Casdin Capital, Llc Acquires 50,000 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) Director Casdin Capital, Llc bought 50,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were acquired at an average price of $52.86 per share, with a total value of $2,643,000.00. Following the purchase, the director owned 3,707,164 shares in the company, valued at $195,960,689.04. This trade represents a 1.37% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Casdin Capital, Llc also recently made the following trade(s):

• On Thursday, June 4th, Casdin Capital, Llc bought 150,000 shares of GeneDx stock. The shares were acquired at an average price of $56.44 per share, with a total value of $8,466,000.00.
• On Wednesday, May 20th, Casdin Capital, Llc bought 140,000 shares of GeneDx stock. The shares were acquired at an average price of $43.81 per share, with a total value of $6,133,400.00.
• On Tuesday, May 19th, Casdin Capital, Llc bought 185,000 shares of GeneDx stock. The shares were acquired at an average price of $42.60 per share, with a total value of $7,881,000.00.
• On Monday, May 18th, Casdin Capital, Llc bought 175,000 shares of GeneDx stock. The shares were acquired at an average price of $42.55 per share, with a total value of $7,446,250.00.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $56.33 on Wednesday. The business has a 50 day moving average price of $55.24 and a 200 day moving average price of $91.57. GeneDx Holdings Corp. has a twelve month low of $32.21 and a twelve month high of $170.87. The company has a market cap of $1.67 billion, a price-to-earnings ratio of -21.02 and a beta of 1.96. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The business had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. During the same quarter in the previous year, the company earned ($0.23) EPS. Research analysts predict that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

Hedge Funds Weigh In On GeneDx

Hedge funds have recently modified their holdings of the stock. Jones Financial Companies Lllp raised its holdings in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after buying an additional 186 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in shares of GeneDx in the 4th quarter worth approximately $27,000. Fifth Third Bancorp acquired a new position in shares of GeneDx in the 1st quarter worth approximately $31,000. Quarry LP raised its holdings in shares of GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after buying an additional 209 shares in the last quarter. Finally, Ramirez Asset Management Inc. acquired a new position in shares of GeneDx in the 4th quarter worth approximately $33,000. 61.72% of the stock is owned by institutional investors and hedge funds.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Casdin Capital, LLC bought 50,000 shares at an average price of $52.86, adding to a recent buying streak that may signal confidence from a major insider. SEC filing
• Positive Sentiment: Casdin Capital also disclosed a larger purchase of 150,000 shares at $56.44 on June 4, reinforcing the impression of insider accumulation after the stock’s recent weakness. SEC filing
• Neutral Sentiment: GeneDx also presented at Goldman Sachs’ Global Healthcare Conference, which may have helped keep the stock in focus, but no major new operating update was highlighted in the transcript. Conference transcript
• Neutral Sentiment: Analyst sentiment remains mixed-to-positive overall, with the stock carrying an average “Moderate Buy” rating, though that view has not changed the near-term legal headline risk. Analyst rating update
• Negative Sentiment: Several law firms issued fresh class-action notices and lead-plaintiff reminders tied to GeneDx’s stock drop after its Q1 results, keeping investor attention on potential securities-fraud claims and litigation uncertainty. Class action alert
• Negative Sentiment: The lawsuits center on alleged misleading disclosures and a steep post-earnings selloff, which may continue to weigh on sentiment despite insider buying. Litigation report

Analyst Upgrades and Downgrades

A number of analysts have commented on WGS shares. Guggenheim reduced their price objective on GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Canaccord Genuity Group set a $75.00 price objective on GeneDx and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Jefferies Financial Group set a $150.00 price objective on GeneDx in a research report on Monday, February 23rd. Craig Hallum reiterated a “buy” rating and issued a $85.00 price objective on shares of GeneDx in a research report on Tuesday, May 5th. Finally, BTIG Research reduced their price objective on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $96.43.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.